– Reuters
GSK’s Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
GSK announced results from phase 3 trials SWIFT-1 and SWIFT-2, showing depemokimab's efficacy and safety in reducing severe asthma exacerbations.
Related Posts
JP Morgan Downgrades Janus Henderson Gr to Underweight, Lowers Price Target to $18
JP Morgan analyst Ken Worthington downgrades Janus Henderson Gr (NYSE:JHG) from Neutral to Underweight and lowers the price target from $27 to $18.
Former Goldman Sachs Exec Beth Hammack Chosen As Next President Of Cleveland Fed
Meet Beth Hammack, the incoming President & CEO of the Federal Reserve Bank of Cleveland. With 30+ years in finance, including roles at Goldman Sachs.